INS and metabolic syndrome: Although our (Martinez-Lemus et al. 2017, Jia et al. 2018a) and other (Nizar et al. 2016) preclinical studies indicate that ENaC inhibitors have a beneficial role in improving glucose metabolism and insulin sensitivity, and preventing metabolic syndrome, clinical data are lacking to provide evidence for the efficacy of ENaC inhibitors in subjects with metabolic syndrome.